Literature DB >> 18371543

Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits.

Olivia Boyer1, Laure-Hélène Noël, Eve Balzamo, Geneviève Guest, Nathalie Biebuyck, Marina Charbit, Rémi Salomon, Véronique Frémeaux-Bacchi, Patrick Niaudet.   

Abstract

We report the first cases of atypical hemolytic and uremic syndrome associated with complement factor H (CFH) deficiency in native kidneys and glomerulonephritis with isolated C3 deposits after kidney transplantation. Two boys developed atypical hemolytic and uremic syndrome at 16 and 11 months of age, associated with low C3 and CFH levels. Both rapidly progressed to end-stage renal failure and received a kidney transplant. Patient 1 had combined CFH and complement factor I (CFI) heterozygous mutations and a membrane cofactor protein (gene symbol, CD46) gene polymorphism. Five years posttransplantation, an allograft biopsy specimen showed numerous mesangial and extramembranous C3 deposits, although the patient had no biological sign of glomerulopathy. Nine years after transplantation, he was well with stable kidney function. Patient 2, who had a homozygous CFH mutation, developed glomerulonephritis with isolated C3 deposits 5 months after kidney transplantation while he was treated for early recurrence of hemolytic anemia. Four years later, the second kidney transplant biopsy specimen showed recurrence of thrombotic microangiopathy. Six years posttransplantation, kidney function was stable and complete blood cell count was normal with regular plasma therapy. These observations suggest that constitutional dysregulation of the alternative pathway is associated with a wide spectrum of kidney diseases, and glomerulonephritis with isolated C3 deposits and thrombotic microangiopathy may be different expressions of the same condition. Several factors could influence the disease, such as degree of CFH haploinsufficiency and other complement alternative pathway regulator abnormalities, such as a membrane cofactor protein polymorphism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18371543     DOI: 10.1053/j.ajkd.2007.11.032

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  18 in total

1.  Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.

Authors:  Elisa Gnappi; Marco Allinovi; Augusto Vaglio; Elena Bresin; Annalisa Sorosina; Francesco P Pilato; Landino Allegri; Lucio Manenti
Journal:  Pediatr Nephrol       Date:  2012-06-05       Impact factor: 3.714

Review 2.  Factor I and factor H deficiency in renal diseases: similar defects in the fluid phase have a different outcome at the surface of the glomerular basement membrane.

Authors:  Peter F Zipfel; Richard J H Smith; Christine Skerka
Journal:  Nephrol Dial Transplant       Date:  2008-12-04       Impact factor: 5.992

3.  Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.

Authors:  Fadi Fakhouri; Elena Goicoechea de Jorge; Frédérique Brune; Philippe Azam; H Terence Cook; Matthew C Pickering
Journal:  Kidney Int       Date:  2010-05-05       Impact factor: 10.612

Review 4.  Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.

Authors:  Andrew S Bomback; Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

5.  Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.

Authors:  Katherine A Vernon; Marieta M Ruseva; H Terence Cook; Marina Botto; Talat H Malik; Matthew C Pickering
Journal:  J Am Soc Nephrol       Date:  2015-09-15       Impact factor: 10.121

Review 6.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

Review 7.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 8.  Treatment options for C3 glomerulopathy.

Authors:  Carla M Nester; Richard J Smith
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-03       Impact factor: 2.894

9.  Complete factor I deficiency due to dysfunctional factor I with recurrent aseptic meningo-encephalitis.

Authors:  Filomeen Haerynck; Patrick Stordeur; Johan Vandewalle; Rudy Van Coster; Victoria Bordon; Frans De Baets; Petra Schelstraete; Cédric Javaux; Marie-Rose Bouvry; Véronique Fremeaux-Bacchi; Joke Dehoorne
Journal:  J Clin Immunol       Date:  2013-10-20       Impact factor: 8.317

10.  Complement C5 is not critical for the formation of sub-RPE deposits in Efemp1 mutant mice.

Authors:  Donita L Garland; Eric A Pierce; Rosario Fernandez-Godino
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.